CSPC Pharma's SYS6052 Shingles Vaccine Enters Phase I/II Clinical Trials in China

Stock News11-02 18:50

CSPC Pharmaceutical Group Limited (01093) has announced that Phase I/II clinical trials for SYS6052, a recombinant herpes zoster virus vaccine (Chinese Hamster Ovary (CHO) cells) developed by the company, have officially commenced in China.

The product is a recombinant protein vaccine developed by the group, composed of the varicella-zoster virus glycoprotein E (gE) protein antigen and a novel nano-adjuvant system independently developed by CSPC Pharma. By optimizing the antigen and nano-adjuvant system, the product is designed to induce strong humoral and cellular immune responses.

The company received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration of the People's Republic of China in July 2026, and subsequently launched a randomized, blinded, controlled Phase I/II clinical trial aimed at evaluating the safety and immunogenicity of the product in individuals aged 40 and above.

Currently, participant recruitment and screening for the clinical trial are being actively advanced.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141819089?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-02 18:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141819089","market":"other","top_or_hot":-1,"title":"CSPC Pharma's SYS6052 Shingles Vaccine Enters Phase I/II Clinical Trials in China","media":"Stock News","content":"<p>CSPC Pharmaceutical Group Limited (01093) has announced that Phase I/II clinical trials for SYS6052, a recombinant herpes zoster virus vaccine (Chinese Hamster Ovary (CHO) cells) developed by the company, have officially commenced in China.<br><br>The product is a recombinant protein vaccine developed by the group, composed of the varicella-zoster virus glycoprotein E (gE) protein antigen and a novel nano-adjuvant system independently developed by CSPC Pharma. By optimizing the antigen and nano-adjuvant system, the product is designed to induce strong humoral and cellular immune responses.<br><br>The company received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration of the People's Republic of China in July 2026, and subsequently launched a randomized, blinded, controlled Phase I/II clinical trial aimed at evaluating the safety and immunogenicity of the product in individuals aged 40 and above.<br><br>Currently, participant recruitment and screening for the clinical trial are being actively advanced.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma's SYS6052 Shingles Vaccine Enters Phase I/II Clinical Trials in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma's SYS6052 Shingles Vaccine Enters Phase I/II Clinical Trials in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-11-02 18:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (01093) has announced that Phase I/II clinical trials for SYS6052, a recombinant herpes zoster virus vaccine (Chinese Hamster Ovary (CHO) cells) developed by the company, have officially commenced in China.<br><br>The product is a recombinant protein vaccine developed by the group, composed of the varicella-zoster virus glycoprotein E (gE) protein antigen and a novel nano-adjuvant system independently developed by CSPC Pharma. By optimizing the antigen and nano-adjuvant system, the product is designed to induce strong humoral and cellular immune responses.<br><br>The company received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration of the People's Republic of China in July 2026, and subsequently launched a randomized, blinded, controlled Phase I/II clinical trial aimed at evaluating the safety and immunogenicity of the product in individuals aged 40 and above.<br><br>Currently, participant recruitment and screening for the clinical trial are being actively advanced.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1226287792.SGD","symbol_name":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","start_time":0,"source_url":"","article_id":"1141819089","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141819089","pubTimestamp":1793616618,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSPC Pharmaceutical Group Limited (01093) has announced that Phase I/II clinical trials for SYS6052, a recombinant herpes zoster virus vaccine (Chinese Hamster Ovary (CHO) cells) developed by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159646":"疫苗","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1521":"挪威政府全球养老基金持仓","BK1515":"抗疫概念","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","01093":"石药集团","PSYK":"PSYK ETF","KURE":"KraneShares MSCI All China Health Care Index ETF","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","MDTX":"Corgi MediaTek 2x Daily ETF","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK1191":"制药","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","BMED":"iShares Health Innovation Active ETF","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC"},"translate_title":"石药集团SYS6052带状疱疹疫苗在中国进入I/II期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"PSYK":1,"01093":1,"IBBQ":1,"IBBJ":1,"KURE":1,"BMED":1,"MDTX":1},"content_text":"CSPC Pharmaceutical Group Limited (01093) has announced that Phase I/II clinical trials for SYS6052, a recombinant herpes zoster virus vaccine (Chinese Hamster Ovary (CHO) cells) developed by the company, have officially commenced in China.The product is a recombinant protein vaccine developed by the group, composed of the varicella-zoster virus glycoprotein E (gE) protein antigen and a novel nano-adjuvant system independently developed by CSPC Pharma. By optimizing the antigen and nano-adjuvant system, the product is designed to induce strong humoral and cellular immune responses.The company received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration of the People's Republic of China in July 2026, and subsequently launched a randomized, blinded, controlled Phase I/II clinical trial aimed at evaluating the safety and immunogenicity of the product in individuals aged 40 and above.Currently, participant recruitment and screening for the clinical trial are being actively advanced.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141819089","isCrawlerRequest":true}